Evidence map›Paper›PMID 24487098›Full record

ArticleJournal of virological methods2014

Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test.

Claude Tayou Tagny, Dora Mbanya, Edward L Murphy, Jean-Jacques Lefrère, Syria Laperche

Open access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virological methods, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Performance of ElecsysDiagnostics (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Update on hepatitis B and C virus diagnosis.World journal of virology · 2015
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Claude Tayou TagnyUniversity Hospital Center, Haematology and Blood Bank Service, Yaoundé, Cameroon; Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Cameroon.
Dora MbanyaUniversity Hospital Center, Haematology and Blood Bank Service, Yaoundé, Cameroon; Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Cameroon.
Edward L MurphyUniversity of California, San Francisco, and Blood Systems Research Institute, San Francisco, USA.
Jean-Jacques LefrèreDepartment for the Study of Blood-borne Agents, Institut National de la Transfusion Sanguine, Paris, France.
Syria LapercheDepartment for the Study of Blood-borne Agents, Institut National de la Transfusion Sanguine, Paris, France; National Reference Center for HBV, HCV, HIV in Transfusion, Institut National de la Transfusion Sanguine, Paris, France. Electronic address: slaperche@ints.fr.
Institut National de la Transfusion Sanguine · FRBlood Systems Research Institute · USUniversité de Yaoundé I · CMUniversity Teaching Hospital of Yaounde · CM

Funding

Health Outcomes in Blood Donors and RecipientsK24HL075036 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MURPHY, EDWARD L · 2004 to 2013
$1.6M
NHLBI NIH HHS K24 HL075036
6 · The paper itself

Abstract

In low-income-countries, screening for hepatitis C virus (HCV) infection is often based on rapid tests (RT). Their lower sensitivity compared to enzyme immunoassay (EIA) suggests that newer HCV Antigen/Antibody (Ag/Ab) combination assays might have a role in such countries. To test this idea, 1998 blood donors were tested at the University Teaching Hospital blood bank in Yaoundé, Cameroon simultaneously with a RT (HCV rapid test, Human Diagnostics, Berlin, Germany) according to standard practice (S1) and with an Ag/Ab assay (Monolisa HCV Ag/Ab Ultra, Biorad, France) (S2). All discordant, borderline and reactive samples were submitted to confirmatory testing by immunoblot and/or HCV-RNA. Of the 86 (4.3%) samples positive with one or both strategies, 29 were confirmed negative, 37 positive and 20 were false positive or resolved infection. There was a significant difference in test sensitivity (p=0.01) between S1 (70.3%) and S2 (91.9%) but not in test specificity (99.4% and 98.6%, respectively). The benefit of the Ag/Ab assay in the detection of recent HCV seronegative infections could not be evaluated since no Antigen-only donations were identified. However, better Ag/Ab test sensitivity compared to RT supports the implementation of these newer immunoassays for HCV screening in the African blood bank setting.

Indexed as

AdultCameroonClinical Laboratory TechniquesDiagnostic Tests, RoutineFemaleHepatitis CHepatitis C AntibodiesHepatitis C AntigensHumansImmunoassayMaleMass ScreeningSensitivity and SpecificityYoung AdultHepatitis C AntibodiesHepatitis C AntigensAfricaAg/Ab combination assayBlood donorsHCVRapid tests

Identifiers

PMID24487098
PMCPMC5042449
OpenAlexW2018765425

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.